Mark Turco, CEO Field Medical
Courtesy of Field Medical
Name: Mark Turco
New title: CEO, Field Medical
Previous title: CEO, Rhode Island Life Science Hub
Field Medical has named Mark Turco as CEO, giving the interventional cardiologist and former Medtronic executive oversight of efforts to develop a second-generation pulsed field ablation system.
The company, which disclosed the appointment Monday, is developing its FieldForce ablation system and FieldBending energy to treat ventricular and atrial arrhythmia. Steven Mickelsen founded the company and was previously its CEO. Mickelsen founded Farapulse, the originator of Boston Scientific’s PFA device, earlier in his career and is now chief technology officer at Field.
Earlier in his career, Turco was chief medical officer of Covidien’s vascular therapies group and Medtronic’s aortic and peripheral vascular business. Since leaving Medtronic in 2017, Turco has held roles including CEO of JC Medical.
At JC, which was part of Genesis Medtech, Turco oversaw development of a transcatheter aortic valve replacement system. Edwards Lifesciences bought JC in 2024. The company paid $116.3 million upfront for JC and committed up to $200 million in milestones, securing TAVR technology for treating people with aortic regurgitation.
Field named Turco CEO after raising $35 million to start a pivotal trial and raising $40 million to complete a first-in-human trial for its PFA system. The company published results from the 26-patient trial in October. Six months after treatment with Field’s PFA device, 82% of patients were free from recurrent ventricular tachycardia and fibrillation or defibrillator shock. Field reported a 98% reduction in ventricular tachycardia and fibrillation burden.
In February, the company shared data from another trial that is testing its device in patients with atrial fibrillation. Field said its PFA device created lesions in less than 200 milliseconds. Vivek Reddy, principal investigator of the trial and an electrophysiologist at Mount Sinai, said in a statement that sub-second delivery provides the flexibility of focal ablation with the efficiency of pulsed field technologies.
Reddy is studying Boston Scientific’s Farapoint PFA catheter in people with ventricular arrhythmias, but companies in the space have initially focused on atrial fibrillation. Ventricular tissue is thicker than atrial tissue, making it harder to create lesions that improve outcomes. Abbott, Boston Scientific, Johnson & Johnson and Medtronic sell PFA devices for atrial fibrillation.
